Search

Fate Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.56 2.4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.49

Max

2.82

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.2M

-31M

Pardavimai

-70K

1.3M

Pelnas, tenkantis vienai akcijai

-0.26

Pelno marža

-2,402.848

Darbuotojai

161

EBITDA

14M

-28M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+115.87% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

67M

321M

Ankstesnė atidarymo kaina

0.16

Ankstesnė uždarymo kaina

2.56

Naujienos nuotaikos

By Acuity

55%

45%

281 / 340 reitingas Healthcare

Fate Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-13 23:36; UTC

Fate Therapeutics shares are higher in after-market hours, reflecting a recovery from earlier declines amid broader market optimism regarding the Federal Reserve's interest rate policy.

2026-08-12 21:02; UTC

Fate Therapeutics Inc. is gaining in after-market trading, rebounding from three consecutive sessions of declines. The price remains above the 20-day moving average.

2026-08-07 20:03; UTC

Fate Therapeutics shares are higher, reaching a session high amid rising U.S. Treasury yields and a weakening U.S. Dollar Index. No specific news identified.

2026-08-06 19:26; UTC

Correlated Moves

Fate Therapeutics Inc shares are lower today, reflecting broader market trends and a decline in the Russell 2000 Index amid ongoing inflation concerns.

2026-08-05 19:56; UTC

Fate Therapeutics shares are higher amid positive market sentiment and falling oil prices, despite some volatility during Wednesday's trading session.

2026-08-04 20:07; UTC

News
Correlated Moves

Fate Therapeutics is gaining as it announces employee inducement awards, including stock options at $2.45 per share. Shares rebounded after an earlier pullback.

2026-08-03 23:01; UTC

News

Fate Therapeutics Inc. shares are lower in after-market trading, despite stronger growth in the manufacturing sector and recent employee inducement awards.

2026-07-29 19:19; UTC

Fate Therapeutics is trading higher amid positive market momentum ahead of the Federal Reserve's monetary policy announcement, despite lingering inflation concerns.

2026-07-28 16:06; UTC

Fate Therapeutics shares are lower amid broader market weakness and investor caution ahead of key earnings reports and the Federal Reserve's interest rate decision.

2026-07-27 21:02; UTC

Fate Therapeutics shares are higher in after-market hours, despite no specific news. Broader market sentiment is improving with rising European equity indices.

2026-07-24 19:07; UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

2026-07-23 21:11; UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

2026-07-22 23:46; UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

2026-07-20 18:26; UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Akcijų palyginimas

Kainos pokytis

Fate Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

115.87% į viršų

12 mėnesių prognozė

Vidutinis 5.44 USD  115.87%

Aukščiausias 8 USD

Žemiausias 2.2 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fate Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

4

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

281 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat